Moleculin Biotech, Inc. — Form SCHEDULE 13D
Filed August 25, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 28/100
What the filing says
Jonathan P. Foster filed a Schedule 13D with the SEC on August 25, 2026, regarding beneficial ownership in Moleculin Biotech, Inc. (a ~$8.8M market-cap pharmaceutical company). The filing itself does not disclose specific share counts, percentage ownership, acquisition dates, or dollar amounts—only that a beneficial ownership statement was filed. Without the detailed ownership data, the concrete terms of this acquisition or stake cannot be determined from this header information alone.
Why this rating
Schedule 13D filings are routine disclosure; significance depends on ownership %, dollar amount, and control implications. Text provides no specifics; cannot assess materiality without ownership threshold data.
See more from August 25, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.